Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD20 is a B cell-specific membrane protein expressed from pre-B cell to mature B cell stages, absent on plasma cells. It plays a role in maintaining the resting membrane organization and the fate of B cells. CD20 does not directly transmit signals but modulates the nanoscale arrangement of B cell surface receptors such as the B cell receptor and coreceptor CD19. Anti-CD20 monoclonal antibodies are widely used for B cell depletion in hematological malignancies and autoimmune diseases, although its precise biological function is not fully understood. CD20’s disruption leads to altered receptor clustering, metabolic reprogramming, and B cell fate switching, underlying its therapeutic and biomarker significance in clinical immunology.
Targeted antibody-induced B cell depletion by antibody-dependent cellular cytotoxicity, complement-mediated cytotoxicity, and apoptosis
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CD20 (B-cell-specific membrane protein) (CD20).